Current answer
Does L-ergothioneine protect cells from oxidative damage?
Laboratory chemistry, transport biology, and human biomarker research make cellular protection a plausible research theme. This profile does not establish that supplementation prevents disease or produces a meaningful clinical benefit.
Before a full review
Profile status
Source collection and claim mapping have begun. Full extraction, cross-examination, adjudication, and human approval are incomplete.
- Direction
- Not assigned
- Evidence stage
- Not assigned
- Certainty
- Not assigned
- Human review
- Not yet started
- Search indexing
- Noindex during development
- Next gate
- Primary-source extraction
Claims being mapped
These are common versions of the topic, not findings that the site endorses. Each requires its own outcome, population, and evidence test.
- Provides antioxidant or cellular protection
- Reduces oxidative stress
- Protects DNA, mitochondria, proteins, or membranes
- Supports cellular resilience or repair
- Accumulates where the body needs protection
Why this benefit has been proposed
The profile records the legitimate research rationale without treating that rationale as proof.
01
Ergothioneine has a dedicated human transporter and can be measured after oral administration.
02
Experimental antioxidant and cellular-stress findings explain why researchers study it.
03
Access to cells and changes in biomarkers do not prove prevention, treatment, or improved function.
Evidence landscape
Evidence categories are kept separate so mechanistic or animal findings do not make the human evidence appear stronger.
No verified randomized clinical-outcome trial specifically testing cellular protection is currently in the database.
A human administration study examined uptake, metabolism, and selected oxidative-damage or inflammation biomarkers.
Observational records may provide exposure context but have not yet been selected for this profile.
Animal evidence has not yet completed a systematic domain-specific review.
The mechanistic literature is the main basis for the claim and therefore requires especially careful separation from human outcomes.
Verified records currently connected
These records have structured pages in the site database. Inclusion here identifies relevance; it is not a positive rating.
Human pharmacokinetic and biomarker study
Administration of pure ergothioneine to healthy human subjects
Why it is relevant: Confirms human exposure and examines selected oxidative-damage and inflammation biomarkers.
Important boundary: Pharmacokinetics and biomarkers do not establish a patient-relevant protective outcome or disease prevention.
Inspect the study record →Questions the full review must resolve
- Which oxidative-damage measures are validated and clinically interpretable?
- Were direct treatment-versus-control biomarker effects prespecified?
- Do biomarker changes translate into improved function or health outcomes?
- Are results independently replicated at comparable exposure?
Current language boundary
- “L-ergothioneine is being investigated in relation to cellular protection.”
- “Evidence mapping and human review are incomplete.”
- “May support cellular protection” only as a research hypothesis, paired with the incomplete-review status.
- Descriptions of individual studies must identify their design and principal limitations.
- Prevents oxidative disease
- Repairs DNA
- Detoxifies cells
- Clinically proven cellular shield
How this becomes a completed review
- 1Preliminary Evidence Profile
Claims, evidence categories, known records, and unresolved questions are mapped.
- 2Draft Evidence Review
Primary sources are extracted and the supporting case, cross-examination, rebuttal, and working adjudication are completed.
- 3Human Review in Progress
A human reviewer checks factual accuracy, interpretation, language, and unresolved risks.
- 4Review Complete
Approval is recorded before direction, evidence stage, certainty, and final language rulings are published.
Transparency record
- Page type
- Preliminary Evidence Profile
- Created
- September 20, 2026
- Evidence status
- Mapping in progress; no verdict assigned
- Human oversight
- Human review not yet started; no review conclusion has been approved
- Search status
- Excluded from search-engine indexing and the XML sitemap during development
- Methodology
- Adversarial Evidence Review Pilot
- AI assistance
- Codex assisted with claim mapping, page structure, and drafting. AI output was not treated as a scientific source.
- Ownership and conflicts
- Published by L-Ergothioneine.com. No active affiliate product links appear on this page.
Educational information only. This preliminary profile does not diagnose, prevent, or treat disease and does not provide personalized supplement advice. Do not start, stop, or change medical care based on this page.
Read the full disclaimer →